Edison Tak-Bun Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Edison Tak-Bun Liu has a total of 477 co-authors. Here are the top co-authors by number of shared publications:
- Carol J. Bult
The Jackson Laboratory
42 shared publications - Joshy George
The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA
42 shared publications - R. Krishna Murthy Karuturi
The Jackson Laboratory
41 shared publications - Allen K. Simons
The Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine
40 shared publications - Anuj Srivastava
The Jackson Laboratory
40 shared publications - Brian J. Sanderson
Affiliation Department of Molecular Biosciences, University of Kansas, Lawrence, Kansas, United States of America
40 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Data from HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications
Purpose:To evaluate HRDetect, a mutational signature–based algorithm, for prognostic utility in tubo-ovarian carcinoma and to determine if whole-genome sequencing (WGS) with rearrangement signature (RS) analysis can refine genomic classification beyond the traditional homologous recombination–deficient versus homologous recombination–proficient framework. Experimental Design:WGS was performed on matched tumor–normal pairs from 185 patients with advanced-stage tubo-ovarian carcinoma from the University of Washington (UW) cohort. HRDetect scores were calculated using substitution signatures, RS, microhomology-mediated deletions, and global loss of heterozygosity. An independent validation cohort (ARIEL2, n = 77) of platinum-sensitive tubo-ovarian carcinoma treated with rucaparib was analyzed to correlate HRDetect with PARP inhibitor (PARPi) response. RS analysis and unsupervised hierarchical clustering were employed to delineate genomic subgroups. Results:In the UW cohort, 51.4% of cases were classified as HRDetect-high and had significantly prolonged median overall survival versus others [6.2 vs. 4.1 years; hazard ratio (HR), 0.6; 95% confidence interval (CI), 0.41–0.87; P = 0.007]. Furthermore, 48.4% of HRDetect-high tumors harbored BRCA1/2 mutations or BRCA1 promoter methylation, whereas 22.1% lacked BRCA1/2 alterations. A substantial fraction (23.2%) fell into an HRDetect-intermediate category, highlighting greater genomic heterogeneity than currently appreciated. RS profiling uncovered 11 genomic clusters, with specific RS profiles (RS1, RS14, and RS18) correlating with poor survival. In ARIEL2, HRDetect-high tumors showed better PARPi responses, with improved progression-free survival (11.1 vs. 7.1 months; HR, 0.44; 95% CI, 0.26–0.74; P = 0.03) and response rates (54% vs. 22.5%). Conclusions:HRDetect predicts survival and sensitivity to PARPi in tubo-ovarian carcinoma. Combined with RS-based clustering, it reveals unappreciated genomic heterogeneity and supports a nuanced stratification framework to improve precision oncology in tubo-ovarian carcinoma.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications
Purpose:To evaluate HRDetect, a mutational signature–based algorithm, for prognostic utility in tubo-ovarian carcinoma and to determine if whole-genome sequencing (WGS) with rearrangement signature (RS) analysis can refine genomic classification beyond the traditional homologous recombination–deficient versus homologous recombination–proficient framework. Experimental Design:WGS was performed on matched tumor–normal pairs from 185 patients with advanced-stage tubo-ovarian carcinoma from the University of Washington (UW) cohort. HRDetect scores were calculated using substitution signatures, RS, microhomology-mediated deletions, and global loss of heterozygosity. An independent validation cohort (ARIEL2, n = 77) of platinum-sensitive tubo-ovarian carcinoma treated with rucaparib was analyzed to correlate HRDetect with PARP inhibitor (PARPi) response. RS analysis and unsupervised hierarchical clustering were employed to delineate genomic subgroups. Results:In the UW cohort, 51.4% of cases were classified as HRDetect-high and had significantly prolonged median overall survival versus others [6.2 vs. 4.1 years; hazard ratio (HR), 0.6; 95% confidence interval (CI), 0.41–0.87; P = 0.007]. Furthermore, 48.4% of HRDetect-high tumors harbored BRCA1/2 mutations or BRCA1 promoter methylation, whereas 22.1% lacked BRCA1/2 alterations. A substantial fraction (23.2%) fell into an HRDetect-intermediate category, highlighting greater genomic heterogeneity than currently appreciated. RS profiling uncovered 11 genomic clusters, with specific RS profiles (RS1, RS14, and RS18) correlating with poor survival. In ARIEL2, HRDetect-high tumors showed better PARPi responses, with improved progression-free survival (11.1 vs. 7.1 months; HR, 0.44; 95% CI, 0.26–0.74; P = 0.03) and response rates (54% vs. 22.5%). Conclusions:HRDetect predicts survival and sensitivity to PARPi in tubo-ovarian carcinoma. Combined with RS-based clustering, it reveals unappreciated genomic heterogeneity and supports a nuanced stratification framework to improve precision oncology in tubo-ovarian carcinoma.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications
Supplementary Figure 1: CONSORT diagram of the UW ovarian cancer cohort
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications
Supplementary Figure 1: CONSORT diagram of the UW ovarian cancer cohort
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications
Supplementary Figure 2: CONSORT diagram of the ARIEL 2 PART 1 clinical trial cohort.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications
Supplementary Figure 2: CONSORT diagram of the ARIEL 2 PART 1 clinical trial cohort.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications
Supplementary Figure 3: Additional genomic characteristics in HRDetect groups.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications
Supplementary Figure 3: Additional genomic characteristics in HRDetect groups.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications
Supplementary Figure 4: Comparative genomic characteristics of HRDetect-intermediate versus high groups
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications
Supplementary Figure 4: Comparative genomic characteristics of HRDetect-intermediate versus high groups
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications
Supplementary Figure 5: Comparative genomic characteristics of HRDetect-intermediate and low groups.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications
Supplementary Figure 5: Comparative genomic characteristics of HRDetect-intermediate and low groups.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications
Supplementary Figure 6: Copy number signatures in UW cohort.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications
Supplementary Figure 6: Copy number signatures in UW cohort.
- 27 May 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (17) , 3899-3910
HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications
Purpose:To evaluate HRDetect, a mutational-signature-based algorithm, for prognostic utility in tubo-ovarian carcinoma (OC), and to determine if whole-genome sequencing (WGS) with rearrangement signature (RS) analysis can refine genomic classification beyond the traditional homologous recombination deficient (HRD) versus proficient (HRP) framework. Experimental Design: WGS was performed on matched tumor-normal pairs from 185 patients with advanced-stage OC from the University of Washington (UW) cohort. HRDetect scores were calculated using substitution signatures, rearrangement signatures, microhomology-mediated deletions, and global loss of heterozygosity. An independent validation cohort (ARIEL2, n = 77) of platinum-sensitive OC treated with rucaparib, was analyzed to correlate HRDetect with PARP inhibitor (PARPi) response. RS analysis and unsupervised hierarchical clustering were employed to delineate genomic subgroups. Results: In the UW cohort, 51.4% of cases were classified as HRDetect-high and had significantly prolonged median overall survival versus others (6.2 vs 4.1 years; HR=0.6; 95% CI=0.41-0.87; p=0.007). 48.4% of HRDetect-high tumors harbored BRCA1/2 mutations or BRCA1 promoter methylation, while 22.1% lacked BRCA1/2 alterations. A substantial fraction (23.2%) fell into an HRDetect-intermediate category, highlighting greater genomic heterogeneity than currently appreciated. RS profiling uncovered eleven genomic clusters, with specific RS profiles (RS1, RS14, RS18) correlating with poor survival. In ARIEL2, HRDetect-high tumors showed better PARPi responses, with improved progression-free survival (11.1 vs 7.1 months; HR=0.44; 95% CI=0.26-0.74; p=0.03) and response rates (54% vs 22.5%). Conclusions: HRDetect predicts survival and sensitivity to PARPi in OC. Combined with RS-based clustering, it reveals unappreciated genomic heterogeneity, and supports a nuanced stratification framework to improve precision oncology in OC.
- 27 May 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (17) , 3899-3910
HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications
Purpose:To evaluate HRDetect, a mutational-signature-based algorithm, for prognostic utility in tubo-ovarian carcinoma (OC), and to determine if whole-genome sequencing (WGS) with rearrangement signature (RS) analysis can refine genomic classification beyond the traditional homologous recombination deficient (HRD) versus proficient (HRP) framework. Experimental Design: WGS was performed on matched tumor-normal pairs from 185 patients with advanced-stage OC from the University of Washington (UW) cohort. HRDetect scores were calculated using substitution signatures, rearrangement signatures, microhomology-mediated deletions, and global loss of heterozygosity. An independent validation cohort (ARIEL2, n = 77) of platinum-sensitive OC treated with rucaparib, was analyzed to correlate HRDetect with PARP inhibitor (PARPi) response. RS analysis and unsupervised hierarchical clustering were employed to delineate genomic subgroups. Results: In the UW cohort, 51.4% of cases were classified as HRDetect-high and had significantly prolonged median overall survival versus others (6.2 vs 4.1 years; HR=0.6; 95% CI=0.41-0.87; p=0.007). 48.4% of HRDetect-high tumors harbored BRCA1/2 mutations or BRCA1 promoter methylation, while 22.1% lacked BRCA1/2 alterations. A substantial fraction (23.2%) fell into an HRDetect-intermediate category, highlighting greater genomic heterogeneity than currently appreciated. RS profiling uncovered eleven genomic clusters, with specific RS profiles (RS1, RS14, RS18) correlating with poor survival. In ARIEL2, HRDetect-high tumors showed better PARPi responses, with improved progression-free survival (11.1 vs 7.1 months; HR=0.44; 95% CI=0.26-0.74; p=0.03) and response rates (54% vs 22.5%). Conclusions: HRDetect predicts survival and sensitivity to PARPi in OC. Combined with RS-based clustering, it reveals unappreciated genomic heterogeneity, and supports a nuanced stratification framework to improve precision oncology in OC.
- Top Cited PapersOpen Access
- 19 May 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (6) , 1282-1293
Differential assembly of mouse and human tumor microenvironments
Mouse models are frequently used to develop treatments for human cancer. However, the degree to which their tumor microenvironments (TMEs) are synonymously assembled is particularly poorly characterized. Through systematic immunoprofiling of 15 commonly used mouse models, we found that most murine TMEs recapitulate the composition of poorly infiltrated human tumors, extensively biased toward high macrophage densities. We discovered substantial species-specific biases of chemokine expression networks known to drive TMEs assembly, together with discoordinated frequencies of T and myeloid cell subtypes. Even with variable alignment, conserved cell-type-specific gene expression programs emerged across species and cohorts. Dissecting the coordinated T cell–myeloid gene expression programs revealed a conserved axis between interferon-responsive myeloid states and ongoing T cell cytotoxicity that transcends tissue of origin and predicts clinical outcome. Collectively, this work provides a practical atlas outlining both the hazards and opportunities of using mice to model human cancer.
- 19 May 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (6) , 1282-1293
Top Cited PapersOpen AccessDifferential assembly of mouse and human tumor microenvironments
Mouse models are frequently used to develop treatments for human cancer. However, the degree to which their tumor microenvironments (TMEs) are synonymously assembled is particularly poorly characterized. Through systematic immunoprofiling of 15 commonly used mouse models, we found that most murine TMEs recapitulate the composition of poorly infiltrated human tumors, extensively biased toward high macrophage densities. We discovered substantial species-specific biases of chemokine expression networks known to drive TMEs assembly, together with discoordinated frequencies of T and myeloid cell subtypes. Even with variable alignment, conserved cell-type-specific gene expression programs emerged across species and cohorts. Dissecting the coordinated T cell–myeloid gene expression programs revealed a conserved axis between interferon-responsive myeloid states and ongoing T cell cytotoxicity that transcends tissue of origin and predicts clinical outcome. Collectively, this work provides a practical atlas outlining both the hazards and opportunities of using mice to model human cancer.
- Open Access
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (3) , e2500854
Prevalence of BRCA1 Promoter Methylation in Cohorts of Individuals With and Without Cancer Assessed by Circulating Cell-Free DNA
PURPOSE: BRCA1 promoter methylation ( BRCA1 meth) affects 20%-27% of triple-negative breast cancer (TNBC) and ovarian cancer (OvCa) and has therapeutic predictive value in both cancer types. BRCA1 meth is established during early embryonic development as a constitutional event, and its detection in the peripheral blood cells of unaffected women associates with increased risk for breast cancer and OvCa. Thus, facile and sensitive assessment of BRCA1 meth is an important component for both risk assessment and the therapeutic management of these cancer types. METHODS: We used the GRAIL circulating cell-free DNA (cfDNA)–based targeted methylation platform to quantify BRCA1 meth in cfDNA (cf BRCA1 meth) from plasma samples of individuals with and without cancer. RESULTS: Detection of cf BRCA1 meth was accurate and sensitive, with an empirical LoD 95 of 0.0081. cf BRCA1 meth was found in 4.1% (113/2,790) of individuals without cancer, and it was significantly more prevalent in females compared with males (4.8% v 2.9%, P = .016), suggesting that the dynamics of BRCA1 promoter methylation and its consequences for cancer development may differ by sex. In a pan-cancer cohort comprising 2,849 patients and representing 15 tissue types, cf BRCA1 meth was enriched only in TNBC (15.2%, P = .001) and OvCa (13.9%, P = .014). Importantly, in these cf BRCA1 meth-positive cases, the fraction of cf BRCA1 meth was correlated with a methylation-based estimate of tumor burden. CONCLUSION: Our findings demonstrate that BRCA1 meth can be robustly detected using cfDNA assessment both as a constitutional event in noncancer samples and as a metric of BRCA1 meth tumor burden in individuals with BRCA1 meth cancers. Therefore, the GRAIL assay provides a single quantitative platform that can be used to explore the role of BRCA1 meth in cancer risk and therapeutic response.
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (3) , e2500854
Open AccessPrevalence of BRCA1 Promoter Methylation in Cohorts of Individuals With and Without Cancer Assessed by Circulating Cell-Free DNA
PURPOSE: BRCA1 promoter methylation ( BRCA1 meth) affects 20%-27% of triple-negative breast cancer (TNBC) and ovarian cancer (OvCa) and has therapeutic predictive value in both cancer types. BRCA1 meth is established during early embryonic development as a constitutional event, and its detection in the peripheral blood cells of unaffected women associates with increased risk for breast cancer and OvCa. Thus, facile and sensitive assessment of BRCA1 meth is an important component for both risk assessment and the therapeutic management of these cancer types. METHODS: We used the GRAIL circulating cell-free DNA (cfDNA)–based targeted methylation platform to quantify BRCA1 meth in cfDNA (cf BRCA1 meth) from plasma samples of individuals with and without cancer. RESULTS: Detection of cf BRCA1 meth was accurate and sensitive, with an empirical LoD 95 of 0.0081. cf BRCA1 meth was found in 4.1% (113/2,790) of individuals without cancer, and it was significantly more prevalent in females compared with males (4.8% v 2.9%, P = .016), suggesting that the dynamics of BRCA1 promoter methylation and its consequences for cancer development may differ by sex. In a pan-cancer cohort comprising 2,849 patients and representing 15 tissue types, cf BRCA1 meth was enriched only in TNBC (15.2%, P = .001) and OvCa (13.9%, P = .014). Importantly, in these cf BRCA1 meth-positive cases, the fraction of cf BRCA1 meth was correlated with a methylation-based estimate of tumor burden. CONCLUSION: Our findings demonstrate that BRCA1 meth can be robustly detected using cfDNA assessment both as a constitutional event in noncancer samples and as a metric of BRCA1 meth tumor burden in individuals with BRCA1 meth cancers. Therefore, the GRAIL assay provides a single quantitative platform that can be used to explore the role of BRCA1 meth in cancer risk and therapeutic response.